Skip NavigationSkip to Content
Return Return to Search Results

Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community

  1. Author:
    Dimond, E. P.
    Zon, R. T.
    Weiner, B. J.
    St Germain, D.
    Denicoff, A. M.
    Dempsey, K.
    Carrigan, A. C.
    Teal, R. W.
    Good, M. J.
    McCaskill-Stevens, W.
    Grubbs, S. S.
    Dimond, E. P.
    Zon, R. T.
    Weiner, B. J.
    St Germain, D.
    Denicoff, A. M.
    Dempsey, K.
    Carrigan, A. C.
    Teal, R. W.
    Good, M. J.
    McCaskill-Stevens, W.
    Grubbs, S. S.

  2. Author Address

    Michiana Hematology Oncology, South Bend, IN; University of North Carolina (UNC) Chapel Hill; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; National Cancer Institute, Bethesda; Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD; and Helen F. Graham Cancer Center and Research Institute, Newark, DE dimonde@mail.nih.gov. Michiana Hematology Oncology, South Bend, IN; University of North Carolina (UNC) Chapel Hill; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; National Cancer Institute, Bethesda; Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD; and Helen F. Graham Cancer Center and Research Institute, Newark, DE.
    1. Year: 2016
    2. Date: Jan
    3. Epub Date: 12/3/2015
  2. Journal: Journal of Oncology Practice
    1. 12
    2. 1
    3. Pages: 63-4, e23-35
  4. Type of Article: Article
  5. ISSN: 1554-7477
  1. Abstract:

    PURPOSE: Several publications have described minimum standards and exemplary attributes for clinical trial sites to improve research quality. The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) developed the clinical trial Best Practice Matrix tool to facilitate research program improvements through annual self-assessments and benchmarking. The tool identified nine attributes, each with three progressive levels, to score clinical trial infrastructural elements from less to more exemplary. The NCCCP sites correlated tool use with research program improvements, and the NCI pursued a formative evaluation to refine the interpretability and measurability of the tool. METHODS: From 2011 to 2013, 21 NCCCP sites self-assessed their programs with the tool annually. During 2013 to 2014, NCI collaborators conducted a five-step formative evaluation of the matrix tool. RESULTS: Sites reported significant increases in level-three scores across the original nine attributes combined (P<.001). Two specific attributes exhibited significant change: clinical trial portfolio diversity and management (P=.0228) and clinical trial communication (P=.0281). The formative evaluation led to revisions, including renaming the Best Practice Matrix as the Clinical Trial Assessment of Infrastructure Matrix (CT AIM), expanding infrastructural attributes from nine to 11, clarifying metrics, and developing a new scoring tool. CONCLUSION: Broad community input, cognitive interviews, and pilot testing improved the usability and functionality of the tool. Research programs are encouraged to use the CT AIM to assess and improve site infrastructure. Experience within the NCCCP suggests that the CT AIM is useful for improving quality, benchmarking research performance, reporting progress, and communicating program needs with institutional leaders. The tool model may also be useful in disciplines beyond oncology.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1200/jop.2015.005181
  3. PMID: 26627979
  4. PMCID: PMC4976452

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel